Skip to main content
Erschienen in: Investigational New Drugs 2/2012

01.04.2012 | SHORT REPORT

A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

verfasst von: Angelica Linnea Quartino, Lena E. Friberg, Mats O. Karlsson

Erschienen in: Investigational New Drugs | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Summary

Purpose To improve the predictive capacity of a semi-mechanistic myelosuppression model for neutrophils as the model have shown to over-predict the nadir of neutrophils and, secondly, to develop a model describing the time-course of leukocytes and neutrophils simultaneously. Experimental Design The study included 601 cancer patients treated with a 1 h infusion of docetaxel in monotherapy. A total of 3,549 pairwise observations of leukocytes and neutrophils from one treatment cycle were analyzed simultaneously in NONMEM. Results A basic model was developed consisting of a neutrophil and a non-neutrophil model, each with the same structure as the semi-mechanistic myelosuppression model. The leukocytes were modeled as the sum of the predicted neutrophils and non-neutrophils. The model described the time-course of the leukocytes well, but was not able to capture the nadir of the neutrophils. Hence the model was further refined and the included modifications (p < 0.001) in the final model are a sigmoid Emax functions for the drug effect, feedback functions on the cell maturation time in bone-marrow and an optimized number of transit compartments for each of the two cell types. Conclusions A joint semi-mechanistic myelosuppression model describing the time-course of leukocytes and neutrophils following docetaxel administration was developed. The data supported a more complex model compared to the previous model developed by Friberg et al. (2002), and increased the model’s capacity to accurately describe the time-course of neutrophils following docetaxel therapy. The combined model also illustrates the differences between the cell types and allows prediction of neutrophil counts from leukocyte measurements.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Zamboni WC, D’Argenio DZ, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ (2001) Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 7(8):2301–2308PubMed Zamboni WC, D’Argenio DZ, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ (2001) Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 7(8):2301–2308PubMed
2.
Zurück zum Zitat Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF (2003) A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math Biosci 186(1):29–41PubMedCrossRef Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF (2003) A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math Biosci 186(1):29–41PubMedCrossRef
3.
Zurück zum Zitat Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63(6):1035–1048PubMedCrossRef Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63(6):1035–1048PubMedCrossRef
6.
Zurück zum Zitat Léger F, Loos WJ, Bugat R, Mathijssen RHJ, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567–578PubMedCrossRef Léger F, Loos WJ, Bugat R, Mathijssen RHJ, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567–578PubMedCrossRef
7.
Zurück zum Zitat Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, Peraire C, Obach R (2006) Phase i dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57(6):727–735PubMedCrossRef Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, Peraire C, Obach R (2006) Phase i dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57(6):727–735PubMedCrossRef
8.
Zurück zum Zitat Van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RAA, Punt CJA, Armand JP, Raymond E, Huitema ADR, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JHM (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investig New Drugs 23(3):225–234CrossRef Van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RAA, Punt CJA, Armand JP, Raymond E, Huitema ADR, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JHM (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investig New Drugs 23(3):225–234CrossRef
9.
Zurück zum Zitat Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57(4):412–426PubMedCrossRef Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57(4):412–426PubMedCrossRef
10.
Zurück zum Zitat Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P (2008) Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (et-743, yondelis) induced neutropenia. Clin Pharmacol Ther 83(1):130–143. doi:10.1038/sj.clpt.6100259 PubMedCrossRef Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P (2008) Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (et-743, yondelis) induced neutropenia. Clin Pharmacol Ther 83(1):130–143. doi:10.​1038/​sj.​clpt.​6100259 PubMedCrossRef
11.
Zurück zum Zitat Brain EGC, Rezai K, Lokiec F, Gutierrez M, Urien S (2008) Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study. Br J Clin Pharmacol 65(4):607–610PubMedCrossRef Brain EGC, Rezai K, Lokiec F, Gutierrez M, Urien S (2008) Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study. Br J Clin Pharmacol 65(4):607–610PubMedCrossRef
12.
Zurück zum Zitat Kathman SJ, Williams DH, Hodge JP, Dar M (2007) A bayesian population pk-pd model of ispinesib-induced myelosuppression. Clin Pharmacol Ther 81(1):88–94PubMedCrossRef Kathman SJ, Williams DH, Hodge JP, Dar M (2007) A bayesian population pk-pd model of ispinesib-induced myelosuppression. Clin Pharmacol Ther 81(1):88–94PubMedCrossRef
13.
Zurück zum Zitat Kathman SJ, Williams DH, Hodge JP, Dar M (2009) A bayesian population pk-pd model for ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemother Pharmacol 63(3):469–476PubMedCrossRef Kathman SJ, Williams DH, Hodge JP, Dar M (2009) A bayesian population pk-pd model for ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemother Pharmacol 63(3):469–476PubMedCrossRef
14.
Zurück zum Zitat Soto E, Staab A, Tillmann C, Trommeshauser D, Fritsch H, Munzert G, Troconiz IF (2010) Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 66(4):785–95 Soto E, Staab A, Tillmann C, Trommeshauser D, Fritsch H, Munzert G, Troconiz IF (2010) Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 66(4):785–95
15.
Zurück zum Zitat Ng CM, Patnaik A, Beeram M, Lin CC, Takimoto CH (2010) Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. Cancer Chemother Pharmacol. doi:10.1007/s00280-010-1393-y Ng CM, Patnaik A, Beeram M, Lin CC, Takimoto CH (2010) Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. Cancer Chemother Pharmacol. doi:10.​1007/​s00280-010-1393-y
16.
Zurück zum Zitat Hansson EK, Wallin JE, Lindman H, Sandström M, Karlsson MO, Friberg LE (2010) Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 65(5):839–848PubMedCrossRef Hansson EK, Wallin JE, Lindman H, Sandström M, Karlsson MO, Friberg LE (2010) Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 65(5):839–848PubMedCrossRef
17.
Zurück zum Zitat Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JHM, Huitema ADR (2008) Pk/pd model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83(6):829–839. doi:10.1038/sj.clpt.6100344 PubMedCrossRef Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JHM, Huitema ADR (2008) Pk/pd model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83(6):829–839. doi:10.​1038/​sj.​clpt.​6100344 PubMedCrossRef
18.
Zurück zum Zitat Zandvliet AS, Schellens JHM, Dittrich C, Wanders J, Beijnen JH, Huitema ADR (2008) Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol 66(4):485–497. doi:10.1111/j.1365-2125.2008.03230.x PubMedCrossRef Zandvliet AS, Schellens JHM, Dittrich C, Wanders J, Beijnen JH, Huitema ADR (2008) Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol 66(4):485–497. doi:10.​1111/​j.​1365-2125.​2008.​03230.​x PubMedCrossRef
19.
Zurück zum Zitat Segura C, Bandres E, Troconiz IF, Garcia-Foncillas J, Sayar O, Dios-Vieitez C, Renedo MJ, Garrido MJ (2004) Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res 21(4):567–573PubMedCrossRef Segura C, Bandres E, Troconiz IF, Garcia-Foncillas J, Sayar O, Dios-Vieitez C, Renedo MJ, Garrido MJ (2004) Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res 21(4):567–573PubMedCrossRef
20.
Zurück zum Zitat Ozawa K, Minami H, Sato H (2007) Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in japanese cancer patients. Cancer Sci 98(12):1985–1992PubMedCrossRef Ozawa K, Minami H, Sato H (2007) Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in japanese cancer patients. Cancer Sci 98(12):1985–1992PubMedCrossRef
21.
Zurück zum Zitat Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23(3):413–421PubMedCrossRef Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23(3):413–421PubMedCrossRef
22.
Zurück zum Zitat Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58(2):143–156PubMedCrossRef Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58(2):143–156PubMedCrossRef
23.
Zurück zum Zitat Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, De Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM (2007) Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the eortc-pamm-nddg. Clin Pharmacokinet 46(12):1051–1068PubMedCrossRef Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, De Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM (2007) Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the eortc-pamm-nddg. Clin Pharmacokinet 46(12):1051–1068PubMedCrossRef
24.
Zurück zum Zitat Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van Der Vijgh WJF, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the european organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13(21):6410–6418. doi:10.1158/1078-0432.CCR-07-0064 PubMedCrossRef Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van Der Vijgh WJF, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the european organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13(21):6410–6418. doi:10.​1158/​1078-0432.​CCR-07-0064 PubMedCrossRef
25.
Zurück zum Zitat Zandvliet AS, Schellens JHM, Copalu W, Beijnen JH, Huitema ADR (2009) Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. J Pharmacokinet Pharmacodyn 36(1):39–62PubMedCrossRef Zandvliet AS, Schellens JHM, Copalu W, Beijnen JH, Huitema ADR (2009) Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. J Pharmacokinet Pharmacodyn 36(1):39–62PubMedCrossRef
26.
Zurück zum Zitat Ramon-Lopez A, Nalda-Molina R, Valenzuela B, Perez-Ruixo JJ (2009) Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients. Pharm Res 26(8):1952–1962PubMedCrossRef Ramon-Lopez A, Nalda-Molina R, Valenzuela B, Perez-Ruixo JJ (2009) Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients. Pharm Res 26(8):1952–1962PubMedCrossRef
27.
Zurück zum Zitat Latz JE, Schneck KL, Nakagawa K, Miller MA, Takimoto CH (2009) Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between japanese and western patients. Clin Cancer Res 15(1):346–354PubMedCrossRef Latz JE, Schneck KL, Nakagawa K, Miller MA, Takimoto CH (2009) Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between japanese and western patients. Clin Cancer Res 15(1):346–354PubMedCrossRef
28.
Zurück zum Zitat Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97(3):290–296PubMedCrossRef Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97(3):290–296PubMedCrossRef
29.
Zurück zum Zitat Joerger M, Huitema ADR, Huizing MT, Willemse PHB, De Graeff A, Rosing H, Schellens JHM, Beijnen JH, Vermorken JB (2007) Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 64(5):622–633PubMedCrossRef Joerger M, Huitema ADR, Huizing MT, Willemse PHB, De Graeff A, Rosing H, Schellens JHM, Beijnen JH, Vermorken JB (2007) Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 64(5):622–633PubMedCrossRef
30.
Zurück zum Zitat Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12(18):5481–5490PubMedCrossRef Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12(18):5481–5490PubMedCrossRef
31.
Zurück zum Zitat Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase ii studies in patients with cancer. J Clin Oncol 16(1):187–196PubMed Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase ii studies in patients with cancer. J Clin Oncol 16(1):187–196PubMed
32.
Zurück zum Zitat Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (taxotere): model building and validation. J Pharmacokinet Biopharm 24(2):153–172PubMedCrossRef Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (taxotere): model building and validation. J Pharmacokinet Biopharm 24(2):153–172PubMedCrossRef
33.
Zurück zum Zitat Ganong W (2010) Review of medical physiology, 23rd edition. The McGraw Hill companies, U.S ISBN: 0‐07‐144040‐2 Ganong W (2010) Review of medical physiology, 23rd edition. The McGraw Hill companies, U.S ISBN: 0‐07‐144040‐2
34.
Zurück zum Zitat Smith CW 2010 Williams hematology 8th edition. The McGraw Hill companies. U.S Book ISBN: 978-0-07-162144-1 Smith CW 2010 Williams hematology 8th edition. The McGraw Hill companies. U.S Book ISBN: 978-0-07-162144-1
35.
Zurück zum Zitat Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ (2000) Models of schedule dependent haematological toxicity of 2′-deoxy-2′-methylidenecytidine (dmdc). Eur J Clin Pharmacol 56(8):567–574PubMedCrossRef Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ (2000) Models of schedule dependent haematological toxicity of 2′-deoxy-2′-methylidenecytidine (dmdc). Eur J Clin Pharmacol 56(8):567–574PubMedCrossRef
36.
Zurück zum Zitat Karlsson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57(3):325–334PubMedCrossRef Karlsson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57(3):325–334PubMedCrossRef
37.
Zurück zum Zitat Beal S, Sheiner L, Boeckmann A, Bauer R (1989–2009) Nonmem user’s guides. Elliot City, MD, USA Beal S, Sheiner L, Boeckmann A, Bauer R (1989–2009) Nonmem user’s guides. Elliot City, MD, USA
38.
Zurück zum Zitat Lindbom L, Pihlgren P, Jonsson EN (2005) Psn-toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using nonmem. Comput Methods Programs Biomed 79(3):241–257PubMedCrossRef Lindbom L, Pihlgren P, Jonsson EN (2005) Psn-toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using nonmem. Comput Methods Programs Biomed 79(3):241–257PubMedCrossRef
39.
Zurück zum Zitat Jonsson EN, Karlsson MO (1999) Xpose–an s-plus based population pharmacokinetic/pharmacodynamic model building aid for nonmem. Comput Methods Programs Biomed 58(1):51–64PubMedCrossRef Jonsson EN, Karlsson MO (1999) Xpose–an s-plus based population pharmacokinetic/pharmacodynamic model building aid for nonmem. Comput Methods Programs Biomed 58(1):51–64PubMedCrossRef
40.
Zurück zum Zitat Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567–578PubMedCrossRef Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567–578PubMedCrossRef
42.
Zurück zum Zitat van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23(3):225–234PubMedCrossRef van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23(3):225–234PubMedCrossRef
43.
Zurück zum Zitat Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86(23):9499–9503PubMedCrossRef Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86(23):9499–9503PubMedCrossRef
44.
Zurück zum Zitat Schmitz S, Franke H, Brusis J, Wichmann HE (1993) Quantification of the cell kinetic effects of g-csf using a model of human granulopoiesis. Exp Hematol 21(6):755–760PubMed Schmitz S, Franke H, Brusis J, Wichmann HE (1993) Quantification of the cell kinetic effects of g-csf using a model of human granulopoiesis. Exp Hematol 21(6):755–760PubMed
45.
Zurück zum Zitat Price TH, Chatta GS, Dale DC (1996) Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 88(1):335–340PubMed Price TH, Chatta GS, Dale DC (1996) Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 88(1):335–340PubMed
46.
Zurück zum Zitat Dancey JT, Deubelbeiss KA, Harker LA, Finch CA (1976) Neutrophil kinetics in man. J Clin Invest 58(3):705–715PubMedCrossRef Dancey JT, Deubelbeiss KA, Harker LA, Finch CA (1976) Neutrophil kinetics in man. J Clin Invest 58(3):705–715PubMedCrossRef
Metadaten
Titel
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model
verfasst von
Angelica Linnea Quartino
Lena E. Friberg
Mats O. Karlsson
Publikationsdatum
01.04.2012
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 2/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9603-3

Weitere Artikel der Ausgabe 2/2012

Investigational New Drugs 2/2012 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.